The role of isolated limb perfusion for melanoma confined to the extremities

Surgical Clinics of North America

Volumn 83, Issue 2, 2003, Pages 371-384

  Eggermont, Alexander M M ^a   Van Geel, Albertus N ^a   De Wilt, Johannes H W ^a   Ten Hagen, Timo L M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; ADRENALIN; BCG VACCINE; BLEOMYCIN; CISPLATIN; DACARBAZINE; DACTINOMYCIN; GAMMA INTERFERON; MELANOMA VACCINE; MELPHALAN; TUMOR NECROSIS FACTOR ALPHA;

BLISTER; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; COMPARTMENT SYNDROME; EDEMA; EPIDERMOLYSIS; ERYTHEMA; HUMAN; HYPERTHERMIC THERAPY; LASER SURGERY; LIMB; LIMB PERFUSION; MELANOMA; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; REVIEW; VACCINATION;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; EXTREMITIES; HUMANS; MELANOMA; SKIN NEOPLASMS;

EID: 0037398375     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6109(02)00095-6     Document Type: Review

References (81)

1. Eggermont AMM, Autier P, Keilholz U. Cutaneous melanoma. In: Souhami RL, Tannock I, Hohemberger P, et al, editors. Oxford Textbook of Oncology. 2nd edition. Oxford: Oxford University Press; 2002. p. 1175-211.
2. Hill S, Thomas JM. Treatment of cutaneous metastases from malignant melanoma using the carbon-dioxide laser. Eur J Surg Oncol 1993;19:173-7.
3. Strobbe LJ, Hart AA, Rumke P, et al. Topical dinitrochlorobenzene combined with systemic dacarbazine in the treatment of recurrent melanoma. Melanoma Res 1997; 7(6):507-12.
4. Storm FK, Sparks FC, Morton DL. Treatment for melanoma of the lower extremity with intralesional injection of bacille Calmette Guerin and hyperthermic perfusion. Surg Gynecol Obstet 1979;149:17-21.
5. Tan JK, Ho VC. Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma. J Dermatol Surg Oncol 1993;19:985-90.
6. Rosso R, Nobile MT, Sertoli MR. Antitumoral activity of human fibroblast interferon administered intranodulary. Oncology 1988;42:86-8.
7. Wussow von P, Block B, Hartmann T, et al. Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer 1988;61:1071-4.
8. Adler A, Stein JA, Kedar E, et al. Intralesional injection of interleukin-2-expanded autologous lymphocytes in melanoma and breast cancer patients: a pilot study. J Biol Response Mod 1984;3(5):491-500.
9. Heller R, Jaroszeski MJ, Reintgen DS, et al. Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. Cancer 1998;83:148-57.
10. Mir LM, Glass LF, Sersa G, et al. Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. Br J Cancer 1998;77:2336-42.
11. Malhotra H, Plosker GL. Cisplatin/epinephrine injectable gel. Drugs Aging 2001;18:787-95.
12. Strobbe LJ, Hart AA, Rumke P, et al. Topical dinitrochlorobenzene combined with systemic dacarbazine in the treatment of recurrent melanoma. Melanoma Res 1997;7:507-12.
13. Rochlitz C, Dreno B, Jantscheff P, et al. Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels. Cancer Gene Ther 2002;9:289-95.
14. Schreiber S, Kampgen E, Wagner E, et al. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: outcome of a phase I study. Hum Gene Ther 1999;10:983-93.
15. Mastrangelo MJ, Maguire HC Jr, Eisenlohr LC, et al. Intratumoral recombinant GMCSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 1999;6:409-22.
16. Marchand M, van Baren N, Weynants P, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999;80:219-30.
17. Seegenschmiedt MH, Keilholz L, Altendorf-Hofmann A, et al. Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience. Int J Radiat Oncol Biol Phys 1999;44:607-18.
18. Calabro A, Singletary SE, Carrasco CH, et al. Intraarterial infusion chemotherapy in regionally advanced malignant melanoma. J Surg Oncol 1990;43:239-44.
19. Bland KI, Kimura AK, Brenner DE, et al. A phase II study of the efficacy of diamminedichloroplatinum (cisplatin) for the control of locally recurrent and intransit malignant melanoma of the extremities using tourniquet outflow-occlusion techniques. Ann Surg 1989;209:73-80.
20. Thompson JF, Waugh RC, Saw RPM, et al. Isolated limb infusion with melphalan for recurrent limb melanoma: a simple alternative to isolataed limb perfusion. Reg Cancer Treat 1994;7:188-92.
21. Creech O, Krementz E, Ryan E, et al. Chemotherapy of cancer: regional perfusion utilising an extracorporeal circuit. Ann Surg 1958;148:616-32.
22. Benckhuijsen C, Kroon BB, van Geel AN, et al. Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur J Surg Oncol 1988;14:157-63.
23. Thompson JF, Gianoutsos MP. Isolated limb perfusion for melanoma - effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg 1992;16:227-33.
24. Klaase JM, Kroon BBR, Van Geel AN, et al. Systemic leakage during isolated limb perfusion for melanoma. Br J Surg 1993;80:1124-6.
25. Wieberdink K, Benckhuijsen C, Braat RP, et al. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982;18:905-10.
26. Eggermont AMM. Treatment of melanoma intransit metastases confined to the limb. Cancer Surv 1996;26:335-49.
27. Omlor G, Gross G, Ecker KW, et al. Optimization of isolated hyperthermic limb perfusion. World J Surg 1993;16:1117-9.
28. Cavaliere R, Ciocatto RC, Giovanella BC, et al. Selective heat sensitivity of cancer cells: biochemical and clinical studies. Cancer 1967;20:1351-81.
29. Clark J, Grabs AJ, Parsosn PG, et al. Melphalan uptake, hyperthermic synergism and drug resistance in a human cell culture model for the isolated limb perfusions of melanoma. Melanoma Res 1994;4:365-70.
30. Klaase JM, Kroon BBR, Van Wijk J, et al. Limb recurrence-free interval and survival in patients with recurrent melanoma of the extremities treated with normothermic isolated perfusion. J Am Col Surg 1994;178:564-72.
31. Klaase JM, Kroon BBR, Van Geel AN, et al. A retrospective comparative study evaluating the results of a single perfusion versus a double perfusion schedule with melphalan in patients with recurrent melanoma of the lower limb. Cancer 1993;71:2990-94.
32. Rosin RD, Westbury G. Isolated limb perfusion for malignant melanoma. Practitioner 1980;224:1031-6.
33. Lejeune FJ, Deloof T, Ewalenko P. Objective regression of unexcised melanoma in-transit metastases after hyperthermic isolation perfusion of the limbs with melphalan. Recent Results Cancer Res 1983;86:268-76.
34. Minor DR, Allen RE, Alberts D, et al. A clinical and pharmokinetic study of isolted limb perfusion with heat and melphalan for melanoma. Cancer 1985;55:2638-44.
35. Skene Al, Bulman AS, Williams TR, et al. Hyperthermic isolated perfusion with melphalan in the treatment of advanced malignant melanoma of the lower limb. Br J Surg 1990;77: 765-767.
36. Kettelhack Ch, Kraus T, Hupp T, et al. Hyperthermic limb perfusion for malignant melanoma and soft tissue sarcoma. Eur J Surg Oncol 1990;16:370-5.
37. Lingam MK, Byrne DS, Aitchison T, et al. A single centre's 10 year experience with isolated limb perfusion in the treatment of recurrentmalignant melanoma of the limb. Eur J Cancer 1996;32A:1668-73.
38. Klaase JM, Kroon BBR, Eggermont AMM, et al. A retrospective comparative study evaluating the results of "mild" hyperthermic versus "controlled" normothermic perfusion for recurrent melanoma of the extremities. Eur J Cancer 1995;31:73-81.
39. Vaglini M, Andreola S, Attili A, et al. Hyperthermic anntiblastic perfusion in the treatment of cancer of the extremities. Tumori 1985;71:355-9.
40. Storm FK, Morton DL. Value of therapeutic hyperthermic limb perfusion in advanced recurrent melanoma of the lower extremity. Am J Surg 1985;150:32-5.
41. Bryant PJ, Balderson GA, Mead P, et al. Hyperthermic isolated limb perfusion for malignant melanoma: response and survival. World J Surg 1995;19:363-8.
42. Di Filippo F, Calabro A, Giannarelli D, et al. Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion. Cancer 1989;63:2551-61.
43. Kroon BBR, Klaase JM, Van Geel AN, et al. Application of hyperthtmermia in regional isolated perfusion for melanoma of the limbs. Reg Cancer Treat 1992;4:223-6.
44. Lindner P, Doubrovsky A, Kam PCA, et al. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol 2002;9:127-36.
45. De Wilt JHW, Lindner P, Colman M, et al. Double isolated limb infusion with cytotoxic agents for recurrent and metastatic limb melanoma [abstract]. Eur J Cancer 2001;37:S80:284.
46. Carswell EA, Old LJ, Kassel RL. An endotoxin induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975;72:3666-70.
47. Asher AL, Mule JJ, Reichert CM, et al. Studies of the antitumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 1987;138:963-74.
48. Lienard D, Ewalenko P, Delmotte JJ, et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992;10:50-62.
49. Lejeune FJ, Lienard D, Leyvraz S, et al. Regional therapy of melanoma. Eur J Cancer 1993;29A:606-12.
50. Hill S, Fawcett WJ, Sheldon J, et al. Low dose tumor necrosis factor-alpha and melphalan in hyperthermic isolated limb perfusion. Br J Surg 1995;80:995-7.
51. Vaglini M, Belli F, Ammatuna M, et al. Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose TNF, gamma-IFN and melphalan. Cancer 1994;73:483-92.
52. Eggermont AMM, Lienard D, Schraffordt Koops H, et al. High dose tumor necrosis factor-alpha in isolation perfusion of the limb: highly effective treatment for melanoma in transit metastases or unresectable sarcoma. Reg Cancer Treat 1995;7:32-6.
53. Fraker DL, Alexander HR, Andrich M, et al. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol 1996; 14:479-89.
54. Lienard D, Eggermont AMM, Schraffordt Koops H, et al. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 1999;9:491-502.
55. Brouckaert PGG, Leroux-Rouls GG, Guisez Y, Tavernier J, et al. In vivo anti-tumor activity of recombinant human and murine TNF, alone and in combination with IFN-gamma on a syngeneic murine melanoma. Int J Cancer 1996;38:763-9.
56. Fraker DL, Alexander HR, Andrich M, et al. Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor. Cancer J Sci Am 1995;1:122.
57. Eggermont AMM, Lienard D, Schraffordt Koops H, et al. Treatment of irresectable soft tissue sarcomas of the limbs by isolation perfusion with high dose TNF-a in combination with gamma-Interferon and melphalan. In: Fiers W, Buurman WA, editors. Tumor necrosis factor: molecular and cellular biology and clinical relevance. Basel: Karger Verlag; 1993. p. 239-243.
58. Eggermont AMM, Schraffordt Koops H, Lienard D, et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial [see comments]. J Clin Oncol 1996a;14:2653-65.
59. Santinami M, Deraco M, Azzarelli A, et al. Treatment of recurrent sarcoma of the extremities by isolated perfusion using tumor necrosis factor alpha and melphalan. Tumori 1996;82:579-84.
60. Eggermont AMM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996b;224:756-764 [discussion: 764-5].
61. Gutman M, Inbar M, Lev-Shlush D, et al. High dose tumor necrosis factor-α and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a <90% response rate and limb preservation. Cancer 1997;79: 1129-37.
62. Eggermont AMM, Schraffordt Koops H, Klausner JM, et al. Limb salvage by isolation limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced extremity soft tissue sarcomas: results of 270 perfusions in 246 patients [abstract]. Proceed ASCO 1999;11:497.
63. Eggermont AMM. TNF registered in Europe: does TNF get a second chance? J Immunother 2000;23:505-6.
64. Bartlett DL, Grace M, Alexander HR, et al. Isolated limb perfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics. Cancer 1997;80:2084-90.
65. McBride CM, Sugarbaker EV, Hickey RC. Prophylactic isolation-perfusion as the primary therapy for invasive malignant melanoma of the limbs. Ann Surg 1975;182:316-24.
66. Schraffordt-Koops H, Vaglini M, Suciu S, et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol 1999;16:2906-12.
67. Hafström L, Rudenstam CM, Blomquist E, et al. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. J Clin Oncol 1991;9:2091-4.
68. Manusama ER, Nooijen PTGA, Stavast J, et al. Synergistic antitumour effect of recombinant human tumour necrosis factor a with melphalan in isolated limb perfusion in the rat. Br J Surg 1996;83:551-5.
69. Manusama ER, Stavast J, Durante NMC, et al. Isolated limb perfusion in a rat osteosarcoma model: a new anti-tumour approach. Eur J Surg Oncol 1996;22:152-7.
70. Nooijen PTGA, Manusama ER, Eggermont AMM, et al. Synergistic antitumour effects of TNF-α and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathologic, immunohistochemical and electron microscopic study. Br J Cancer 1996;74:1908-15.
71. De Wilt JHW, ten Hagen TLM, de Boeck G, et al. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 2000;82:1000-3.
72. Veen vd AH, Wilt de JHW, Eggermont AMM, et al. TNF-α augments intratumoural concentration of doxorubicin in TNF-α-based isolated limb perfusion in rat sarcoma models and enhances antitumour effects. Br J Cancer 1996;82:973-80.
73. Kristensen CA, Nozue M, Boucher Y, et al. Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts. Br J Cancer 1996;74:533-6.
74. DeWilt JHW, Manusama ER, van Tiel ST, et al. Prerequisites for effective isolated limb perfusion using tumour necrosis factor-alpha and melphalan in rats. Br J Cancer 1999;80:161-6.
75. Rossi CR, Foletto M, Di Filippo F, et al. Soft tissue limb sarcomas: Italian clinical trials with hyperthermic antiblastic perfusion. Cancer 2000;86:1742-9.
76. Manusama ER, de Wilt JHW, ten Hagen TLM, et al. Toxicity and antitumor activity of interferon-gamma alone and in combinations with TNF and melphalan in isolated limb perfusion in the BN175 sarcoma tumor model in rats. Oncol Rep 1999;6:173-7.
77. DeWilt JHW, Manusama ER, van Etten B, et al. Inhibition of nitric oxide synthesis by LNAME results in synergistic antitumour activity with melpahlan and tumour necrosis factor-alpha-based isolated limb. Br J Cancer 2000;83:1176-82.
78. Seynhaeve ALB, de Wilt JHW, van Tiel ST, et al. Combination of Actinomycin D with TNF-a in isolated limb perfusion results in improved tumour response in soft tissue sarcoma-bearing rats but is accompanied by severe dose limiting local toxicity. Br J Cancer 2002;86:1174-9.
79. Milas M, Feig B, Yu D, et al. Isolated limb perfusion in the sarcoma-bearing rat: a novel preclinical gene delivery system. Clin Cancer Res 1997;3:2197-203.
80. Roos de WK, de Wilt JHW, van der Kaaden ME, et al. Isolated limb perfusion for local gene delivery: efficient and targeted adenovirus-mediated gene transfer into soft tissue sarcomas. Ann Surg 2000;232:814-21.
81. De Wilt JHW, Bout A, Eggermont AMM, et al. Adenoviru-mediated IL-3β gene transfer using isolated limb perfusion inhibits growth of limb sarcoma in rats. Hum Gene Ther 2001;12:489-502.